<DOC>
	<DOCNO>NCT01793077</DOCNO>
	<brief_summary>Tremodi observational , non-interventional , prospective , open-label , non-comparative study collect real life data treatment Depo-Eligard® 3 different administration male prostate cancer patient . Once examine physician decide therapeutic approach selection criterion fulfil , propose patient participate study . An informed consent form collect participant study . There 2 possible study visit coincide routine consultation , namely visit 1 ( inclusion visit ) visit 2 ( end study visit ) . On visit , Adverse Drug Reactions ( adverse event cause Depo-Eligard® ) collect patient ask complete Quality Of Life questionnaire ( EORTC QLQ-C30 ) . At visit 2 , examine physician give global evaluation treatment Depo-Eligard® assess treatment benefit patient . Testosterone Prostate Specific Antigen ( PSA ) blood value collect visit , available .</brief_summary>
	<brief_title>Observational , Non-interventional , Non Comparative Real Life Data Collection Depo-Eligard® 7.5 mg , 22.5 mg 45 mg Male Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Patients prescribe DepoEligard® 7.5 mg 22.5 mg 45 mg accordance term market authorization .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Phase 4</keyword>
	<keyword>Data collection</keyword>
	<keyword>Observational</keyword>
	<keyword>Depo-Eligard</keyword>
	<keyword>Prospective</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Treatment</keyword>
</DOC>